PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN
Introduction: Recombined human erythropoietin has been present in clinical practice for more than 20 years, in these therapeutic indications: anemia in kidney insufficiency, anemia during chemotherapy of tumors, prevention of anemias that appear in premature born babies, it is used for increasing autologous blood cell levels before blood transfusion, AIDS joined anemia (intensified by zidovudine), anemia joined with chronic inflammatory conditions such as rheumatoid arthritis(still in research phase). During the course of Erythropoietin treatment side effects have been noticed, that include multiple organ systems, and have different levels of frequency. Major number of studies shows connection between erythropoietin treatment and bone marrow aplasia, but small number of them states clearly defined side-effect that explains this phenomenon.
Objective: Goal of this paper is to analyze available case studies of bone marrow aplasia during erythropoietin application, access their quality and causality of every study.
Method: Research of literature used for the preparation of this systematic review has been conducted during the period of November- December 2017. In search for literature medical base PubMed has been used. Inclusion criteria were: available full article, publications in English language, publications conducted on humans, and case report studies. Eight studies passed selection.
Results: results were presented by 5 charts: documentation size, credibility, number of case study reports of side-effects in the paper that was graded, Naranjo causality score, data extraction chart. Mean grade value of the studies quality was 7,0, while mean Naranjo score was 6,6.
Ristić Z. Hematopoiesis. In: Ristić M, Ristić S. Hematology with transfusiology. Beograd 2011.p.54.
Skorecki K Chronic kidney failure. In: Harrisons principles of internal medicine 15th edition, Beograd. Brad – Fin & Romanov, 2004. p.1511.
Lewin A. Indetification of patients and risk factors in chronic kidney disease-ebaluating risk factors and therapeutic strategies. Nephro lDail Transplant. 2001; 16 (Suppl 7): 57- 60.
Barbone FP, Johnson DL Farrell FX, Collins A, Middleton SA, McMahon FJ, et al. New epoetin molecules and novel therapeutic approaches.Nephrol Dial Transplant. 1999; 14 (Suppl 2): 80-4.
Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989; 321(3):158-63.
Jejlkmann W. Molecular biology od erythropoietin. Intern Med. 2004; 43(8): 649-59.
Rang HP, Dale MM, Ritter JM, Moore PK. Farmakologija. Beograd: Data status; 2005.
Levin A. Recombinant of patinents and risk factors in chronic kidney disease evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001; 16 (Suppl 7): 57-60 .
Stanulović M. Biotechnological drugs with expired patent protection. In: Prostran M, Stanulović M, Marisavljević D, Djurić D. Farmaceutska medicina. Beograd: Medicinski fakultet Univerziteta u Beogradu, 2009: p 205.
Yoshimi M, Kadowaki Y, Kikuchi Y, Takahashi T. Coombs-negative autoimmune hemolytic anemia followed by anti-erythropoetin receptor antibody-associated pure red cell aplasia: a case report and review of literature. Intern Med. 2016;55(5):511-4.
Manent L, Vaglio A. Pure red cell aplasia followed by disseminated intravascular coagulation in a haemodialysis patient receiving erythropoietin-β. Nephrol Dial Transplant.2007: 22 (5):1465-7.
Okoshi Y, Imagawa S, Higuchi M, Yoshida C, Shimizu S, Mukai HY et al. A patient with acquired pure red cell aplasia showing a positive antiglobulin test and the presence of inhibitor against erythroid precursors. Intern Med. 2002; 41(7):589-92.
Snanoudj R, Beaudreuil S, Arzouk N, Jacq D, Casadevall N, Charpentier B et al. Recovery from pure red cell aplasia caused by anti‐erythropoietin antibodies after kidney transplantation. Am J transplant. 2004;4(2):274-7.
Lee H, Yang J, Kim H, Kwon JW, Oh KH, Joo KW et al. Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously. J Korean Med Sci. 2010;25(11):1676-9.
Asari A, Gokal R.. Pure red cell aplasia secondary to epoetin alpha responding to darbepoetin alpha in a patient on peritoneal dialysis. J Am Soc Nephrol. 2004;15(8):2204-7.
Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002;13(9): 2381–3.
Chng WJ, Tan LK, Liu TC. Cyclosporine treatment for patients with CRF who developed pure red blood сell aplasia following EPO therapy. Am J Kidney Dis. 2003. 41(3):692-5.
- There are currently no refbacks.
Copyright (c) 2018 Filip Mihajlovic, Aleksandar Milosavljevic, Dusan Djuric
This work is licensed under a Creative Commons Attribution 4.0 International License.